Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method

被引：33

作者：

Dijkstra, Jacob A. ^{[1
]}

Sturkenboom, Marieke G. G. ^{[1
]}

van Hateren, Kai ^{[1
]}

Koster, Remco A. ^{[1
]}

Greijdanus, Ben ^{[1
]}

Alffenaar, Jan-Willem C. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, NL-9700 RB Groningen, Netherlands

来源：

BIOANALYSIS | 2014年 / 6卷 / 16期

关键词：

TANDEM-MASS-SPECTROMETRY; BLOOD SPOT ANALYSIS; TUBERCULOSIS; AMINOGLYCOSIDES; MOXIFLOXACIN; TOXICITY; DRUGS;

D O I：

10.4155/bio.14.191

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Amikacin and kanamycin are frequently used in the treatment of multidrug-resistant TB. The current commercially available immunoassay is unable to analyze kanamycin and trough levels of amikacin. The objective was therefore to develop a LC-MS/MS method for the quantification of amikacin and kanamycin in human serum. Materials & methods: Using apramycin as internal standard, selectivity, accuracy, precision, recovery, matrix effects and stability were evaluated. Results: The presented LC-MS/MS method meets the recommendations of the US FDA with a low LLOQ of 250 ng/ml for amikacin and 100 ng/ml for kanamycin. No statistical significant difference was found between the LC-MS/MS method and the immunoassay of amikacin (Architect((R)) assay, p = 0.501). Conclusion: The low LLOQ of amikacin and the ability to analyze kanamycin makes the LC-MS/MS method the preferred method for analyzing these aminoglycosides.

引用

页码：2125 / 2133

页数：9

共 25 条

[1] Dried Blood Spot Analysis Combined With Limited Sampling Models Can Advance Therapeutic Drug Monitoring of Tuberculosis Drugs [J].